ABSTRACT
BACKGROUND: Most dementia disorders have a clear genetic background and a number of disease genes have been identified. Mutations in the tau gene (MAPT) lead to frontotemporal dementia (FTD), whereas mutations in the genes for the amyloid-ß precursor protein (APP) and the presenilins (PSEN1, PSEN2) cause early-onset, dominantly inherited forms of Alzheimer's disease (AD). Even if mutations causing Mendelian forms of these diseases are uncommon, elucidation of the pathogenic effects of such mutations have proven important for understanding the pathogenic processes. Here, we performed a screen to identify novel pathogenic mutations in known disease genes among patients undergoing dementia investigation. RESULTS: Using targeted exome sequencing we have screened all coding exons in eleven known dementia genes (PSEN1, PSEN2, APP, MAPT, APOE, GRN, TARDBP, CHMP2B, TREM2, VCP and FUS) in 102 patients with AD, FTD, other dementia diagnoses or mild cognitive impairment. We found three AD patients with two previously identified pathogenic mutations in PSEN1 (Pro264Leu and Met146Val). In this screen, we also identified the recently reported APP mutation in two siblings with AD. This mutation, named the Uppsala mutation, consists of a six amino acid intra-amyloid ß deletion. In addition, we found several potentially pathogenic mutations in PSEN2, FUS, MAPT, GRN and APOE. Finally, APOE ε4 was prevalent in this patient group with an allele frequency of 54%. CONCLUSIONS: Among the 102 screened patients, we found two disease causing mutations in PSEN1 and one in APP, as well as several potentially pathogenic mutations in other genes related to neurodegenerative disorders. Apart from giving important information to the clinical investigation, the identification of disease mutations can contribute to an increased understanding of disease mechanisms.
Subject(s)
Alzheimer Disease , Frontotemporal Dementia , Alzheimer Disease/genetics , Amyloid beta-Peptides , Frontotemporal Dementia/genetics , Humans , Membrane Glycoproteins , Mutation , Presenilin-1/genetics , Presenilin-2/genetics , Receptors, ImmunologicABSTRACT
BACKGROUND: Neuroinflammatory processes are common in neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal dementia (FTD), but current knowledge is limited as to whether cerebrospinal fluid (CSF) levels of neuroinflammatory proteins are altered in these diseases. OBJECTIVE: To identify and characterize neuroinflammatory signatures in CSF from patients with AD, mild cognitive impairment (MCI), and FTD. METHODS: We used proximity extension assay and ANOVA to measure and compare levels of 92 inflammatory proteins in CSF from 42 patients with AD, 29 with MCI due to AD (MCI/AD), 22 with stable MCI, 42 with FTD, and 49 control subjects, correcting for age, gender, collection unit, and multiple testing. RESULTS: Levels of matrix metalloproteinase-10 (MMP-10) were increased in AD, MCI/AD, and FTD compared with controls (AD: fold change [FC]â=â1.32, 95% confidence interval [CI] 1.14-1.53, qâ=â0.018; MCI/AD: FCâ=â1.53, 95% CI 1.20-1.94, qâ=â0.045; and FTD: FCâ=â1.42, 95% CI 1.10-1.83, qâ=â0.020). MMP-10 and eleven additional proteins were increased in MCI/AD, compared with MCI (qâ<â0.05). In FTD, 36 proteins were decreased, while none was decreased in AD or MCI/AD, compared with controls (qâ<â0.05). CONCLUSION: In this cross-sectional multi-center study, we found distinct patterns of CSF inflammatory marker levels in FTD and in both early and established AD, suggesting differing neuroinflammatory processes in the two disorders.
Subject(s)
Alzheimer Disease/cerebrospinal fluid , Amyloid beta-Peptides/cerebrospinal fluid , Cognitive Dysfunction/cerebrospinal fluid , Frontotemporal Dementia/cerebrospinal fluid , Inflammation/cerebrospinal fluid , Aged , Alzheimer Disease/diagnosis , Biomarkers/cerebrospinal fluid , Cognitive Dysfunction/diagnosis , Cross-Sectional Studies , Female , Frontotemporal Dementia/diagnosis , Humans , Inflammation/diagnosis , Male , Middle Aged , Peptide Fragments/cerebrospinal fluid , tau Proteins/cerebrospinal fluidABSTRACT
Point mutations in the amyloid precursor protein gene (APP) cause familial Alzheimer's disease (AD) by increasing generation or altering conformation of amyloid ß (Aß). Here, we describe the Uppsala APP mutation (Δ690-695), the first reported deletion causing autosomal dominant AD. Affected individuals have an age at symptom onset in their early forties and suffer from a rapidly progressing disease course. Symptoms and biomarkers are typical of AD, with the exception of normal cerebrospinal fluid (CSF) Aß42 and only slightly pathological amyloid-positron emission tomography signals. Mass spectrometry and Western blot analyses of patient CSF and media from experimental cell cultures indicate that the Uppsala APP mutation alters APP processing by increasing ß-secretase cleavage and affecting α-secretase cleavage. Furthermore, in vitro aggregation studies and analyses of patient brain tissue samples indicate that the longer form of mutated Aß, AßUpp1-42Δ19-24, accelerates the formation of fibrils with unique polymorphs and their deposition into amyloid plaques in the affected brain.
Subject(s)
Alzheimer Disease , Amyloid beta-Peptides , Alzheimer Disease/genetics , Amyloid Precursor Protein Secretases/metabolism , Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Brain/metabolism , HumansABSTRACT
Mutations in the progranulin (PGRN) gene have recently been identified in families with frontotemporal lobar degeneration and ubiquitin-positive brain inclusions linked to chromosome 17q21. We have previously described a Swedish family displaying frontotemporal dementia with rapid progression and linkage to chromosome 17q21. In this study, we performed an extended clinical and neuropathological investigation of affected members of the family and a genetic analysis of the PGRN gene. There was a large variation of the initial presenting symptoms in this family, but common clinical features were non-fluent aphasia and loss of spontaneous speech as well as personality and behavioural changes. Mean age at onset was 54 years with disease duration of close to 4 years. Neuropathological examination revealed frontotemporal neurodegeneration with ubiquitin and TAR DNA binding protein-43 immunoreactive intraneuronal inclusions. Mutation screening of the PGRN gene identified a 1 bp deletion in exon 1 causing a frameshift of the coding sequence and introducing a premature termination codon in exon 2 (Gly35GlufsX19). Analysis of PGRN messenger RNA (mRNA) levels revealed a considerable decrease in lymphoblasts from mutation carriers and fragment size separation, and sequence analysis confirmed that the mutated mRNA allele was almost absent in these samples. In conclusion, the PGRN Gly35fs mutation causes frontotemporal dementia with variable clinical presentation in a large Swedish family, most likely through nonsense-mediated decay of mutant PGRN mRNA and resulting haploinsufficiency.
Subject(s)
Dementia/genetics , Intercellular Signaling Peptides and Proteins/genetics , Mutation , Age of Onset , Base Sequence , Cell Line , DNA Mutational Analysis , Dementia/physiopathology , Female , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Pedigree , Progranulins , SwedenABSTRACT
BACKGROUND/AIMS: Alterations in gene dosage have recently been associated with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, and deletions of the progranulin (PGRN) locus were recently described in patients with frontotemporal lobar degeneration (FTLD). FTLD is a genetically complex neurodegenerative disorder with mutations in the PGRN and the microtubule-associated protein tau (MAPT) genes being the most common known causes of familial FTLD. In this study, we investigated 39 patients with FTLD, previously found negative for mutations in PGRN and MAPT, for copy number alterations of these 2 genes. METHODS: Gene dosage analysis of PGRN and MAPT was performed using multiplex ligation-dependent probe amplification. RESULTS: We did not identify any PGRN or MAPT gene dosage variations in the 39 FTLD patients investigated. CONCLUSION: We therefore conclude that alterations in gene copy number of PGRN and MAPT are not a cause of disease in this collection of FTLD patients.
Subject(s)
Frontotemporal Lobar Degeneration/genetics , Gene Dosage , Intercellular Signaling Peptides and Proteins/genetics , tau Proteins/genetics , Gene Deletion , Gene Duplication , Humans , Nucleic Acid Amplification Techniques , ProgranulinsABSTRACT
We describe a case of late onset neurodegeneration with brain iron accumulation (NBIA) presenting as frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS). A male patient presented at age 66 with change of personality: disinhibition, emotional blunting, and socially inappropriate behavior, coupled with dysarthria, dystonia, and corticospinal tract involvement. Magnetic resonance imaging showed general cortical atrophy, iron deposits in the globus pallidus, and the "eye of the tiger" sign. Neuropsychologic performance was globally reduced, especially executive functions. Fluorodeoxyglucose positron emission tomography showed hypometabolism predominantly in frontal and temporal areas. Repeated neurophysiologic examinations showed signs of chronic denervation. The patient was diagnosed with NBIA but fulfilled consensus criteria for FTD and had a clinical picture of ALS, without neurophysiologic confirmation. Our finding introduces NBIA as a possible cause of FTD and as a differential diagnosis of the FTD-ALS complex.
Subject(s)
Amyotrophic Lateral Sclerosis/physiopathology , Brain/pathology , Frontotemporal Dementia/physiopathology , Pantothenate Kinase-Associated Neurodegeneration/physiopathology , Aged , Brain/metabolism , Diagnosis, Differential , Electromyography , Humans , Iron/metabolism , Magnetic Resonance Imaging , Male , Neuropsychological Tests , Pantothenate Kinase-Associated Neurodegeneration/diagnosis , Pantothenate Kinase-Associated Neurodegeneration/pathology , Pedigree , Positron-Emission TomographyABSTRACT
BACKGROUND: Alzheimer's disease (AD) is diagnosed based on a clinical evaluation as well as analyses of classical biomarkers: Aß42, total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF). Although the sensitivities and specificities of the classical biomarkers are fairly good for detection of AD, there is still a need to develop novel biochemical markers for early detection of AD. OBJECTIVE: We explored if integration of novel proteins with classical biomarkers in CSF can better discriminate AD from non-AD subjects. METHODS: We applied ELISA, mass spectrometry, and multivariate modeling to investigate classical biomarkers and the CSF proteome in subjects (nâ=â206) with 76 AD patients, 74 mild cognitive impairment (MCI) patients, 11 frontotemporal dementia (FTD) patients, and 45 non-dementia controls. The MCI patients were followed for 4-9 years and 21 of these converted to AD, whereas 53 remained stable. RESULTS: By combining classical CSF biomarkers with twelve novel markers, the area of the ROC curves (AUROCS) of distinguishing AD and MCI/AD converters from non-AD were 93% and 96%, respectively. The FTDs and non-dementia controls were identified versus all other groups with AUROCS of 96% and 87%, respectively. CONCLUSIONS: Integration of new and classical CSF biomarkers in a model-based approach can improve the identification of AD, FTD, and non-dementia control subjects.
Subject(s)
Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/diagnosis , Adult , Aged , Aged, 80 and over , Amyloid beta-Peptides/cerebrospinal fluid , Biomarkers/cerebrospinal fluid , Cognitive Dysfunction/cerebrospinal fluid , Cognitive Dysfunction/diagnosis , Diagnosis, Differential , Disease Progression , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Frontotemporal Dementia/cerebrospinal fluid , Frontotemporal Dementia/diagnosis , Humans , Male , Mass Spectrometry , Middle Aged , Peptide Fragments/cerebrospinal fluid , Proteome , Sensitivity and Specificity , tau Proteins/cerebrospinal fluidABSTRACT
The Alzheimer's disease (AD)-related peptide amyloid-ß (Aß) has a propensity to aggregate into various assemblies including toxic soluble Aß protofibrils. Several studies have reported the existence of anti-Aß antibodies in humans. However, it is still debated whether levels of anti-Aß antibodies are altered in AD patients compared to healthy individuals. Formation of immune complexes with plasma Aß makes it difficult to reliably measure the concentration of circulating anti-Aß antibodies with certain immunoassays, potentially leading to an underestimation. Here we have investigated anti-Aß antibody production on a cellular level by measuring the amount of anti-Aß antibody producing cells instead of the plasma level of anti-Aß antibodies. To our knowledge, this is the first time the anti-Aß antibody response in plasma has been compared in AD patients and age-matched healthy individuals using the enzyme-linked immunospot (ELISpot) technique. Both AD patients and healthy individuals had low levels of B cells producing antibodies binding Aß40 monomers, whereas the number of cells producing antibodies toward Aß42 protofibrils was higher overall and significantly higher in AD compared to healthy controls. This study shows, by an alternative and reliable method, that there is a specific immune response to the toxic Aß protofibrils, which is significantly increased in AD patients.
Subject(s)
Alzheimer Disease/blood , Alzheimer Disease/immunology , Amyloid beta-Peptides/immunology , Autoantibodies/metabolism , B-Lymphocytes/metabolism , Peptide Fragments/immunology , Aged , Aged, 80 and over , Amyloid beta-Peptides/metabolism , Biotinylation , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry , Humans , Male , Mental Status Schedule , Peptide Fragments/metabolismABSTRACT
BACKGROUND: The Arctic mutation (p.E693G/p.E22G)fs within the ß-amyloid (Aß) region of the ß-amyloid precursor protein gene causes an autosomal dominant disease with clinical picture of typical Alzheimer's disease. Here we report the special character of Arctic AD neuropathology in four deceased patients. RESULTS: Aß deposition in the brains was wide-spread (Thal phase 5) and profuse. Virtually all parenchymal deposits were composed of non-fibrillar, Congo red negative Aß aggregates. Congo red only stained angiopathic vessels. Mass spectrometric analyses showed that Aß deposits contained variably truncated and modified wild type and mutated Aß species. In three of four Arctic AD brains, most cerebral cortical plaques appeared targetoid with centres containing C-terminally (beyond aa 40) and variably N-terminally truncated Aß surrounded by coronas immunopositive for Aßx-42. In the fourth patient plaque centres contained almost no Aß making the plaques ring-shaped. The architectural pattern of plaques also varied between different anatomic regions. Tau pathology corresponded to Braak stage VI, and appeared mainly as delicate neuropil threads (NT) enriched within Aß plaques. Dystrophic neurites were scarce, while neurofibrillary tangles were relatively common. Neuronal perikarya within the Aß plaques appeared relatively intact. CONCLUSIONS: In Arctic AD brain differentially truncated abundant Aß is deposited in plaques of variable numbers and shapes in different regions of the brain (including exceptional targetoid plaques in neocortex). The extracellular non-fibrillar Aß does not seem to cause overt damage to adjacent neurons or to induce formation of neurofibrillary tangles, supporting the view that intracellular Aß oligomers are more neurotoxic than extracellular Aß deposits. However, the enrichment of NTs within plaques suggests some degree of intra-plaque axonal damage including accumulation of hp-tau, which may impair axoplasmic transport, and thereby contribute to synaptic loss. Finally, similarly as the cotton wool plaques in AD resulting from exon 9 deletion in the presenilin-1 gene, the Arctic plaques induced only modest glial and inflammatory tissue reaction.
Subject(s)
Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/genetics , Brain/metabolism , Mutation , Aged , Alzheimer Disease/pathology , Brain/pathology , Family , Humans , Middle Aged , Pedigree , Sweden , White People/geneticsABSTRACT
Amyloid-ß (Aß) oligomers of different sizes and forms have recently been the focus formany Alzheimer's disease (AD) researchers. Various immunoassays have been used to detect low concentrations of these elusive Aß species in different forms of human samples using little or no sample dilutions. However, the possibility that positive results may be caused by interference from heterophilic antibodies (HA) is often overlooked. HA, which recognize immunoglobulins from other species, are present in human plasma and cerebrospinal fluid (CSF) and may cause interference in sandwich immunoassays like enzyme-linked immunosorbent assays (ELISAs) by cross-binding the capture and detection antibodies of the assay. They thus may generate a false positive signal. Here we show that when assessing the Aß oligomer content in plasma samples from 44 individuals with a sandwich ELISA, none of the 21 positive signals remained when the assay was repeated in the presence of factors blocking HA. Similarly, in CSF samples from 104 individuals, the signals from the 22 positive samples were strongly reduced when analyzed after anti-HA treatment. Taken together, HA interference is a problem that needs to be addressed when measuring low levels of an antigen in human plasma and CSF samples.
Subject(s)
Amyloid beta-Peptides/blood , Amyloid beta-Protein Precursor/immunology , Antibodies, Heterophile/blood , Aged , Aged, 80 and over , Alzheimer Disease/blood , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/immunology , Amyloid beta-Peptides/cerebrospinal fluid , Amyloid beta-Protein Precursor/blood , Amyloid beta-Protein Precursor/cerebrospinal fluid , Animals , Antibodies, Heterophile/cerebrospinal fluid , Binding Sites, Antibody/immunology , Biomarkers/blood , Enzyme-Linked Immunosorbent Assay/standards , False Positive Reactions , Humans , Mice , Mice, Transgenic , Middle Aged , Protein Multimerization/immunologyABSTRACT
Recently, the P86L alteration in CALHM1 (calcium homeostasis modulator-1) was reported to be associated with Alzheimer's disease (AD). Moreover, the risk allele increased amyloid-beta (A beta) levels in conditioned media from cultured cells. Therefore, we hypothesized that CALHM1 P86L may modulate A beta or tau levels in cerebrospinal fluid (CSF). Nearly 200 individuals with AD or other cognitive disorders were included for CSF analysis and CALHM1 genotyping. No significant differences in CSF levels of A beta 42, tau or phospho-tau were found across the various CALHM1 genotypes. In conclusion, we found no evidence that CALHM1 P86L is associated with altered CSF levels of the investigated AD biomarkers.
Subject(s)
Amyloid beta-Peptides/cerebrospinal fluid , Calcium Channels/genetics , Membrane Glycoproteins/genetics , Peptide Fragments/cerebrospinal fluid , Polymorphism, Genetic , tau Proteins/cerebrospinal fluid , Aged , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/genetics , Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Biomarkers/cerebrospinal fluid , Biomarkers/metabolism , Calcium Channels/metabolism , Cognition Disorders/cerebrospinal fluid , Cognition Disorders/genetics , Cognition Disorders/metabolism , Cohort Studies , Female , Finland , Genotype , Humans , Male , Membrane Glycoproteins/metabolism , Peptide Fragments/metabolism , Phosphorylation , Sequence Analysis, DNA , Sweden , White People/genetics , tau Proteins/metabolismABSTRACT
Alzheimer's disease (AD) is a genetically complex disorder, and several genes related to cholesterol metabolism have been reported to contribute to AD risk. To identify further AD susceptibility genes, we have screened genes that map to chromosomal regions with high logarithm of the odds scores for AD in full genome scans and are related to cholesterol metabolism. In a European screening sample of 115 sporadic AD patients and 191 healthy control subjects, we analyzed single nucleotide polymorphisms in 28 cholesterol-related genes for association with AD. The genes HMGCS2, FDPS, RAFTLIN, ACAD8, NPC2, and ABCG1 were associated with AD at a significance level of P < or = 0.05 in this sample. Replication trials in five independent European samples detected associations of variants within HMGCS2, FDPS, NPC2, or ABCG1 with AD in some samples (P = 0.05 to P = 0.005). We did not identify a marker that was significantly associated with AD in the pooled sample (n = 2864). Stratification of this sample revealed an APOE-dependent association of HMGCS2 with AD (P = 0.004). We conclude that genetic variants investigated in this study may be associated with a moderate modification of the risk for AD in some samples.